Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 28, 2025
Product Development
Caribou: Solving the allogeneic problem with CRISPR
Caribou selected a de-risked target and modality to take on multiplexed editing
BioCentury | May 3, 2023
Discovery & Translation
Rapid identification of improved antibody variants; plus peptide-assisted genome editing and more
BioCentury’s roundup of translational news
BioCentury | Jul 28, 2022
Regulation
July 27 Quick Takes: Cidara, Melinta in deal for antifungal headed to FDA
Plus Legend gains after upsizing financing and updates from Lexicon, ObsEva, Cassava, Legend and more
BioCentury | Jul 30, 2021
Translation in Brief
Stanford, Tempus unveil high-throughput screening platforms; plus Blueprint, Editas, Prothena, AlzeCure and more
BioCentury’s roundup of translational news
BioCentury | Nov 14, 2020
Emerging Company Profile
Metagenomi hunts for new gene editing systems with $65M series A
Emerging Company Profile: Bay Area newco debuts with round led by Leaps by Bayer and Humboldt Fund
BioCentury | Jun 6, 2020
Translation in Brief
Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more
BioCentury’s roundup of preclinical news
BioCentury | May 23, 2020
Translation in Brief
A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock
BioCentury’s roundup of preclinical news
BioCentury | Feb 29, 2020
Product Development
CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak
COVID-19 could give CRISPR diagnostics their first proof of principle
BioCentury | Feb 19, 2020
Product Development
COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more
Items per page:
1 - 10 of 45